
  
    
      
        Background_NNP
        Patients_NNS following_VBG total_JJ hip_NN and_CC knee_NN arthroplasty_NN are_VBP
        at_IN a_DT significant_JJ risk_NN for_IN thromboembolic_JJ complications_NNS ._.
        Despite_IN modern_JJ prophylaxis_NNS against_IN thromboembolism_NN ,_, studies_NNS
        still_RB report_VBP a_DT 10_CD to_TO 40_CD %_NN frequency_NN of_IN deep_JJ venous_JJ
        thrombosis_NNS and_CC a_DT significant_JJ rate_NN of_IN pulmonary_JJ embolism_NN
        following_VBG total_JJ hip_NN or_CC knee_NN arthroplasty_NN [_NN [_NN 1_CD 2_CD 3_CD ]_NN ]_NN ._. The_DT
        high_JJ incidence_NN of_IN thrombotic_JJ disease_NN despite_IN prophylaxis_NNS
        makes_VBZ early_JJ detection_NN imperative_JJ ,_, as_IN treatment_NN with_IN
        anticoagulation_NN is_VBZ highly_RB effective_JJ [_NN 4_CD ,_, 5_CD ]_NN ._.
        Both_DT DVT_NNP and_CC PE_NNP manifest_JJ few_JJ specific_JJ clinical_JJ signs_NNS or_CC
        symptoms_NNS ,_, making_VBG the_DT clinical_JJ diagnosis_NN neither_DT sensitive_JJ
        nor_CC specific_JJ [_NN [_NN 5_CD 6_CD 7_CD ]_NN ]_NN ._. A_DT high_JJ index_NN of_IN suspicion_NN based_VBN
        on_IN risk_NN stratification_NN is_VBZ necessary_JJ for_IN the_DT detection_NN and_CC
        appropriate_JJ implementation_NN of_IN diagnostic_JJ studies_NNS to_TO
        identify_VB this_DT complication_NN ._. The_DT ability_NN preoperatively_RB to_TO
        identify_VB a_DT subset_NN of_IN patients_NNS undergoing_VBG adult_NN
        reconstructive_JJ surgery_NN that_WDT are_VBP at_IN a_DT higher_JJR risk_NN of_IN
        developing_VBG thromboembolic_JJ complications_NNS would_MD aid_VB the_DT
        clinician_NN in_IN making_VBG an_DT accurate_JJ diagnosis_NN and_CC make_VB possible_JJ
        further_JJ research_NN to_TO determine_VB optimal_NN regimes_NNS of_IN
        postoperative_JJ detection_NN and_CC prophylaxis_NNS ._.
        Until_IN recently_RB ,_, the_DT only_RB known_VBN hypercoagulable_JJ states_NNS
        were_VBD several_JJ rare_JJ genetic_JJ disorders_NNS of_IN the_DT coagulation_NN
        cascade_NN (_( antithrombin_NN III_NNP ,_, protein_NN C_NNP ,_, and_CC protein_NN S_NNP
        deficiency_NN )_) ,_, which_WDT accounted_VBD for_IN only_RB a_DT small_JJ percentage_NN of_IN
        all_DT patients_NNS with_IN venous_JJ thrombosis_NNS [_NN 16_CD ]_NN ._. In_IN 1993_CD ,_,
        Dahlback_NNP et_CC al_NN ._. [_NN 17_CD ]_NN described_VBD a_DT previously_RB unreported_JJ
        hypercoagulable_JJ state_NN among_IN members_NNS of_IN three_CD families_NNS that_WDT
        suffered_VBD from_IN recurrent_JJ venous_JJ thrombosis_NNS ._. Further_RB
        investigation_NN revealed_VBD an_DT autosomal-dominant_JJ inherited_VBN
        defect_NN in_IN the_DT anticoagulant_NN function_NN of_IN factor_NN V_NNP resulting_VBG
        in_IN resistance_NN to_TO the_DT anticoagulant_NN action_NN of_IN activated_VBN
        protein_NN C_NNP (_( APC_NNP )_) [_NN 18_CD ]_NN ._. Formal_NNP evidence_NN for_IN this_DT association_NN
        came_VBD from_IN a_DT large_JJ population-based_JJ patient-control_JJ study_NN ,_,
        the_DT Leiden_NNP Thrombophilia_NNP Study_NNP ,_, which_WDT followed_VBD 474_CD
        consecutive_JJ patients_NNS of_IN less_JJR than_IN 70_CD years_NNS of_IN age_NN with_IN a_DT
        first_JJ episode_NN of_IN objectively_RB confirmed_VBD DVT_NNP [_NN 9_CD ]_NN ._.
        Twenty-eight_NNP percent_NN of_IN patients_NNS in_IN the_DT study_NN group_NN and_CC
        5_CD ._. 7_CD %_NN of_IN controls_NNS were_VBD found_VBN to_TO be_VB APC-resistant_NNP ._.
        Furthermore_RB ,_, it_PRP was_VBD estimated_VBN that_IN these_DT patients_NNS have_VBP a_DT
        sevenfold_NN greater_JJR risk_NN of_IN developing_VBG a_DT DVT_NNP ._. The_DT abnormal_JJ
        factor_NN V_NNP that_IN causes_NNS APC_NNP resistance_NN was_VBD subsequently_RB termed_VBN
        factor_NN V_NNP Leiden_NNP ._. Later_RB studies_VBZ confirmed_VBD a_DT seven-_NN
        to-eightfold_JJ increased_VBN risk_NN for_IN patients_NNS heterozygous_JJ for_IN
        the_DT factor_NN V_NNP mutation_NN and_CC an_DT 80_CD -_: fold_VB increased_VBN risk_NN in_IN
        homozygous_JJ individuals_NNS [_NN 3_CD ,_, 9_CD ]_NN ._. Factor_NN V_NNP Leiden_NNP is_VBZ
        therefore_RB the_DT most_RBS common_JJ thrombophilic_JJ disorder_NN described_VBD ,_,
        10_CD times_NNS more_RBR common_JJ than_IN all_PDT the_DT other_JJ genetic_JJ
        coagulopathies_NNS combined_VBN ,_, with_IN an_DT estimated_VBN prevalence_NN of_IN 5_CD %_NN
        in_IN the_DT general_JJ population_NN [_NN 9_CD ,_, 10_CD ,_, 15_CD ]_NN ._.
        Polymorphisms_NNP of_IN the_DT angiotensin_NN converting_VBG enzyme_NN have_VBP
        also_RB been_VBN associated_VBN with_IN a_DT hypercoaguable_JJ state_NN ._. The_DT
        angiotensin_NN converting_VBG enzyme_NN (_( ACE_NNP )_) digests_NNS angiotensin_NN I_PRP
        to_TO angiotensin_NN II_NNP (_( a_DT potent_JJ vasoconstrictor_NN )_) and_CC is_VBZ thus_RB
        involved_VBN with_IN the_DT regulation_NN of_IN vascular_NN tone_NN ._. The_DT
        angiotensin_NN converting_VBG enzyme_NN has_VBZ also_RB been_VBN shown_VBN to_TO
        attenuate_NN fibrinolysis_NNS and_CC affect_VB both_DT platelet_NN activation_NN
        and_CC aggregation_NN [_NN 14_CD ]_NN ._. The_DT ACE_NNP gene_NN has_VBZ been_VBN found_VBN to_TO have_VB
        a_DT polymorphism_NN consisting_VBG of_IN an_DT insertion_NN and_CC a_DT deletion_NN of_IN
        a_DT 287_CD base_NN pair_NN fragment_NN of_IN intron_NN 16_CD [_NN 13_CD ]_NN ._. Patients_NNS may_MD
        thus_RB be_VB of_IN one_CD of_IN three_CD separate_JJ genotypes_NNS ;_:
        insertion_NN /_NN insertion_NN ,_, deletion_NN /_NN deletion_NN or_CC
        insertion_NN /_NN deletion_NN ._. Patients_NNS with_IN the_DT deletion_NN /_NN deletion_NN
        genotype_NN have_VBP been_VBN shown_VBN to_TO have_VB mean_VB plasma_NN ACE_NNP levels_NNS of_IN
        approximately_RB twice_RB that_IN of_IN patients_NNS with_IN the_DT
        insertion_NN /_NN insertion_NN genotype_NN [_NN 13_CD ]_NN ._. Thus_RB patients_NNS with_IN the_DT
        deletion_NN /_NN deletion_NN genotype_NN may_MD be_VB at_IN increased_VBN risk_NN for_IN
        thromboembolic_JJ events_NNS ._.
        Although_IN the_DT majority_NN of_IN patients_NNS undergoing_VBG total_JJ hip_NN
        and_CC knee_NN arthroplasty_NN are_VBP subjected_VBN to_TO similar_JJ
        perioperative_JJ risk_NN factors_NNS that_WDT predispose_VB to_TO
        thromboembolism_NN ,_, only_RB a_DT subset_NN of_IN patients_NNS develop_VBP this_DT
        complication_NN ._. The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO determine_VB
        whether_IN the_DT FVL_NNP mutation_NN or_CC the_DT deletion_NN polymorphism_NN of_IN
        the_DT ACE_NNP gene_NN is_VBZ associated_VBN with_IN a_DT higher_JJR risk_NN of_IN developing_VBG
        a_DT postoperative_JJ thromboembolic_JJ complication_NN ._.
      
      
        Patients_NNS and_CC Methods_NNP
        
          Patients_NNS
          The_DT presence_NN of_IN the_DT Factor_NN V_NNP Leiden_NNP mutation_NN and_CC the_DT
          deletion-deletion_JJ polymorphism_NN of_IN the_DT angiotensin_NN
          converting_VBG enzyme_NN gene_NN were_VBD determined_VBN for_IN 38_CD patients_NNS
          who_WP developed_VBD symptomatic_JJ pulmonary_JJ embolism_NN (_( 30_CD
          patients_NNS )_) or_CC proximal_NN deep_JJ venous_JJ thrombosis_NNS (_( 8_CD patients_NNS )_)
          following_VBG elective_JJ total_JJ hip_NN or_CC knee_NN arthroplasty_NN at_IN our_PRP$
          institution_NN between_IN February_NNP of_IN 1997_CD and_CC July_NNP of_IN 1999_CD ._.
          The_DT prevalence_NN of_IN these_DT genetic_JJ profiles_NNS was_VBD compared_VBN to_TO
          a_DT control_NN cohort_NN of_IN 241_CD patients_NNS who_WP had_VBD undergone_VBN
          similar_JJ procedures_NNS between_IN November_NNP 1997_CD and_CC March_NNP of_IN
          1998_CD at_IN the_DT same_JJ institution_NN and_CC whose_WP$ postoperative_JJ
          course_NN was_VBD not_RB complicated_VBN by_IN symptomatic_JJ thromboembolism_NN
          using_VBG an_DT unmatched_JJ case-control_JJ design_NN ._. A_DT total_NN of_IN 321_CD
          elective_JJ total_JJ hip_NN and_CC knee_NN arthroplasties_NNS were_VBD performed_VBN
          during_IN the_DT time_NN period_NN that_IN samples_NNS for_IN the_DT control_NN group_NN
          were_VBD collected_VBN ,_, however_RB 14_CD patients_NNS chose_VBD not_RB to_TO
          participate_VB in_IN the_DT study_NN and_CC 7_CD patients_NNS were_VBD discharged_VBN
          to_TO home_NN prior_RB to_TO sample_NN collection_NN ._. An_DT additional_JJ 59_CD
          patients_NNS who_WP were_VBD clinically_RB suspected_VBN of_IN deep_JJ vein_NN
          thrombosis_NNS but_CC had_VBD a_DT single_JJ negative_JJ duplex_NN ultrasound_NN of_IN
          the_DT lower-extremities_JJ were_VBD also_RB excluded_VBN from_IN the_DT
          analysis_NN ._.
          Pulmonary_NNP embolism_NN was_VBD diagnosed_VBN on_IN the_DT basis_NN of_IN
          clinical_JJ symptoms_NNS and_CC signs_NNS combined_VBN with_IN a_DT high_JJ
          probability_NN ventilation-perfusion_JJ scan_VB in_IN 20_CD of_IN the_DT 30_CD ,_, a_DT
          positive_JJ pulmonary_JJ angiogram_NN in_IN 6_CD ,_, a_DT positive_JJ high_JJ
          resolution_NN chest_NN CT_NNP in_IN 2_CD and_CC an_DT intermediate_JJ probability_NN
          ventilation-perfusion_JJ scan_VB combined_VBN with_IN a_DT high_JJ clinical_JJ
          suspicion_NN in_IN 2_CD ._. The_DT 8_CD proximal_NN deep_JJ venous_JJ thrombosis_NNS was_VBD
          diagnosed_VBN by_IN duplex_NN ultrasonography_NN in_IN seven_CD and_CC contrast_NN
          venography_NN in_IN 1_CD ._. Thirty-one_NNP of_IN the_DT 38_CD patients_NNS were_VBD
          treated_VBN with_IN intravenous_JJ heparin_NN followed_VBN by_IN oral_JJ
          warfarin_NN ,_, five_CD by_IN placement_NN of_IN an_DT inferior_JJ vena_NN caval_NN and_CC
          oral_JJ warfarin_NN and_CC two_CD by_IN placement_NN of_IN an_DT inferior_JJ vena_NN
          caval_NN filter_NN followed_VBN by_IN intravenous_JJ heparin_NN and_CC oral_JJ
          warfarin_NN
          Demographic_NNP and_CC operative_JJ information_NN including_VBG
          relevant_JJ past_JJ medical_JJ history_NN and_CC the_DT type_NN of_IN
          thromboembolic_JJ prophylaxis_NNS utilized_JJ was_VBD collected_VBN for_IN the_DT
          experimental_JJ and_CC control_NN groups_NNS as_IN summarized_VBD in_IN Table_NNP 1_CD ._.
          Approval_NNP was_VBD obtained_VBN from_IN the_DT Institutional_NNP Review_NNP Board_NNP
          at_IN our_PRP$ hospital_NN prior_RB to_TO initiating_VBG this_DT study_NN and_CC all_DT
          patients_NNS signed_VBD informed_VBN consent_NN prior_RB to_TO participating_VBG
          in_IN the_DT study_NN ._.
        
        
          Determination_NNP of_IN the_DT Factor_NN V_NNP Leiden_NNP
          Mutation_NNP
          Two-milliliter_NNP samples_NNS of_IN whole_JJ blood_NN were_VBD collected_VBN
          in_IN buffered_JJ sodium_NN citrate_NN ,_, and_CC high_JJ molecular_JJ weight_NN
          genomic_JJ DNA_NNP was_VBD obtained_VBN from_IN the_DT peripheral_JJ blood_NN
          leukocyte_NN fraction_NN (_( QIAamp_NNP Blood_NNP Tissue_NNP Kit_NNP ,_, Qiagen_NNP ,_,
          Valencia_NNP CA_NNP )_) ._. The_DT factor_NN V_NNP Leiden_NNP mutation_NN is_VBZ located_VBN in_IN
          exon_NN 10_CD ,_, 11_CD nucleotides_NNS 5_CD '_POS of_IN the_DT start_NN of_IN intron_NN 10_CD at_IN
          nucleotide_NN 1691_CD ,_, where_WRB an_DT adenosine_NN replaces_VBZ guanidine_NN [_NN
          15_CD ]_NN ._. A_DT 169_CD -_: base-pair_JJ DNA_NNP fragment_NN of_IN the_DT factor_NN V_NNP gene_NN
          that_WDT includes_VBZ nucleotide_NN 1691_CD was_VBD amplified_VBN utilizing_VBG the_DT
          polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) with_IN the_DT forward_JJ primer_NN
          5_CD '_POS CATACTACAGTGACGTGGAC_NNP 3_CD '_POS and_CC the_DT reverse_JJ primer_NN
          5_CD '_POS GACCTAACATGTTCTAGCCAGAAG_NNP 3_CD '_'' ._. PCR_NNP was_VBD performed_VBN using_VBG a_DT
          standard_JJ protocol_NN as_IN follows_VBZ with_IN a_DT final_JJ volume_NN of_IN 50_CD
          μl_NN ;_: 5_CD μl_NN 10_CD X_NNP PCR_NNP buffer_NN ,_, 5_CD μl_NN 2_CD mM_NN dNTP_NN ,_, 5_CD μl_NN forward_RB
          primer_NN (_( concentration_NN 20_CD ng_NN /_NN ul_NN )_) ,_, 5_CD ul_NN reverse_NN primer_NN
          (_( concentration_NN 20_CD ng_NN /_NN ul_NN )_) ,_, 1_CD ._. 5_CD μl_NN 50_CD mM_NN MgCl_NNP ,_, 0_CD ._. 25_CD μl_NN Taq_NNP
          polymerase_NN (_( 5_CD U_NNP /_NN μl_NN )_) ,_, and_CC 1_CD μl_NN sample_NN purified_JJ genomic_JJ DNA_NNP
          (_( concentration_NN approximately_RB 30_CD ng_NN /_NN μl_NN )_) (_( PCR_NNP reagents_NNS ,_,
          Gibco-_NNP BRL_NNP ,_, Bethesda_NNP ,_, MD_NNP )_) ._. Thirty-five_CD cycles_NNS of_IN the_DT
          polymerase_NN chain_NN reaction_NN utilizing_VBG a_DT microprocessor_NN
          controlled_VBD thermal_JJ cycler_NN (_( Perkin-_NNP Elmer_NNP ,_, Norwalk_NNP ,_, CT_NNP )_)
          were_VBD then_RB performed_VBN to_TO amplify_VB the_DT desired_VBN segment_NN
          utilizing_VBG the_DT following_JJ parameters_NNS ;_: 94_CD °_NN C_NNP for_IN denaturation_NN
          for_IN 45_CD seconds_NNS ,_, 63_CD °_NN C_NNP for_IN 60_CD seconds_NNS for_IN annealing_VBG ,_, and_CC
          72_CD °_NN C_NNP for_IN 90_CD seconds_NNS for_IN extension_NN ._.
          The_DT amplified_VBN 169_CD -_: base-pair_JJ fragment_NN was_VBD digested_VBN with_IN
          0_CD ._. 4_CD U_NNP of_IN the_DT restriction_NN enzyme_NN 
          Mnl_NNP I_PRP (_( New_NNP England_NNP Bio_NNP Labs_NNPS ,_,
          Beverly_NNP ,_, MA_NNP )_) at_IN 37_CD °_NN C_NNP for_IN 6_CD -_: 12_CD hours_NNS and_CC the_DT resulting_VBG
          fragments_NNS were_VBD subjected_VBN to_TO electrophoresis_NNS on_IN 4_CD %_NN
          Nu-_NNP Sieve_NNP GTG_NNP agarose_NN gels_NNS (_( FMC_NNP Bioproducts_NNP ,_, Rockland_NNP ,_, ME_NNP )_)
          and_CC the_DT nucleotide_NN bands_NNS visualized_JJ by_IN ethidium_NN bromide_NN
          fluorescence_NN and_CC photography_NN ._. Digestion_NNP yields_VBZ three_CD
          fragments_NNS (_( 86_CD ,_, 46_CD ,_, and_CC 37_CD base_NN pairs_NNS )_) in_IN the_DT normal_JJ
          allele_NN and_CC two_CD fragments_NNS (_( 123_CD and_CC 46_CD base_NN pairs_NNS )_) in_IN the_DT
          mutant_JJ allele_NN as_IN the_DT point_NN mutation_NN at_IN position_NN 1691_CD is_VBZ
          associated_VBN with_IN loss_NN of_IN the_DT recognition_NN site_NN for_IN 
          Mnl_NNP I_PRP ._. Control_NNP digestions_NNS were_VBD
          performed_VBN with_IN fragments_NNS amplified_VBN from_IN cloned_VBN DNA_NNP with_IN
          and_CC without_IN the_DT factor_NN V_NNP Leiden_NNP mutation_NN ._.
        
        
          Determination_NNP of_IN Angiotensin_NNP Converting_NNP Enzyme_NNP
          Polymorphisms_NNP
          The_DT insertion_NN /_NN deletion_NN genotype_NN of_IN subjects_NNS was_VBD
          performed_VBN using_VBG purified_JJ genomic_JJ DNA_NNP (_( prepared_VBN as_IN above_IN )_)
          and_CC the_DT polymerase_NN chain_NN reaction_NN using_VBG the_DT forward_JJ
          primer_NN 5_CD '_POS CTGGAGACCACTCCCATCCTTTCT_NNP 3_CD '_POS and_CC the_DT reverse_JJ
          primer_NN 5_CD '_POS GATGTGGCCATCACATTCGTCAGAT_NNP 3_CD '_POS as_IN per_IN Rigat_NNP et_CC al_NN [_NN
          13_CD ]_NN ._. PCR_NNP was_VBD performed_VBN using_VBG a_DT standard_JJ protocol_NN as_IN
          follows_VBZ with_IN a_DT final_JJ volume_NN of_IN 50_CD μl_NN ;_: 5_CD μl_NN 10_CD X_NNP PCR_NNP
          buffer_NN ,_, 5_CD μl_NN 2_CD mM_NN dNTP_NN ,_, 5_CD μl_NN forward_RB primer_NN
          (_( concentration_NN 20_CD ng_NN /_NN ul_NN )_) ,_, 5_CD μl_NN reverse_NN primer_NN
          (_( concentration_NN 20_CD ng_NN /_NN μl_NN )_) ,_, 1_CD ._. 5_CD μl_NN 50_CD mM_NN MgCl_NNP ,_, 0_CD ._. 25_CD μl_NN Taq_NNP
          polymerase_NN (_( 5_CD U_NNP /_NN μl_NN )_) ,_, and_CC 1_CD μl_NN sample_NN purified_JJ genomic_JJ DNA_NNP
          (_( concentration_NN approximately_RB 30_CD ng_NN /_NN μl_NN )_) ,_, and_CC 5_CD μl_NN dimethyl_NN
          sulfoxide_NN ._. Thirty-five_CD cycles_NNS of_IN the_DT polymerase_NN chain_NN
          reaction_NN utilizing_VBG a_DT microprocessor_NN controlled_VBD thermal_JJ
          cycler_NN (_( Perkin-_NNP Elmer_NNP ,_, Norwalk_NNP ,_, CT_NNP )_) were_VBD then_RB performed_VBN to_TO
          amplify_VB the_DT desired_VBN segment_NN utilizing_VBG the_DT following_JJ
          parameters_NNS ;_: 94_CD °_NN C_NNP for_IN denaturation_NN for_IN 60_CD seconds_NNS ,_, 63_CD °_NN C_NNP
          for_IN 90_CD seconds_NNS for_IN annealing_VBG ,_, and_CC 72_CD °_NN C_NNP for_IN 90_CD seconds_NNS for_IN
          extension_NN ._. The_DT PCR_NNP products_NNS were_VBD subjected_VBN to_TO
          electrophoresis_NNS on_IN 1_CD ._. 2_CD %_NN agarose_NN gels_NNS and_CC the_DT nucleotide_NN
          bands_NNS visualized_JJ by_IN ethidium_NN bromide_NN fluorescence_NN and_CC
          photography_NN ._. A_DT 190_CD -_: bp_NN fragment_NN characterizes_VBZ the_DT deletion_NN
          polymorphism_NN ,_, while_IN the_DT presence_NN of_IN the_DT insertion_NN leads_VBZ
          to_TO a_DT 490_CD -_: bp_NN fragment_NN ._. Heterozygotes_NNP exhibit_NN an_DT
          intermediate_JJ band_NN that_WDT is_VBZ most_RBS likely_JJ a_DT heteroduplex_NN DNA_NNP
          fragment_NN ._.
        
      
      
        Statistical_NNP Analysis_NNP
        Statistical_NNP analysis_NN was_VBD performed_VBN using_VBG a_DT two-tailed_JJ
        student_NN 's_POS t_NN test_NN ,_, Chi_NNP square_JJ analysis_NN or_CC Mann-_NNP Whitney_NNP U_NNP
        test_NN where_WRB appropriate_JJ with_IN a_DT significance_NN set_VBN at_IN p_NN =_SYM 0_CD ._. 05_CD ._.
        Assuming_VBG an_DT unmatched_JJ case_NN control_NN design_NN with_IN alpha_NN =_SYM 0_CD ._. 05_CD
        and_CC beta_NN =_SYM 0_CD ._. 80_CD ,_, post-hoc_JJ power_NN analysis_NN was_VBD performed_VBN to_TO
        determine_VB the_DT minimum_JJ detectable_JJ relative_JJ risk_NN detectable_JJ
        with_IN the_DT given_VBN sample_NN size_NN [_NN 24_CD ]_NN ._.
      
      
        Results_NNS
        A_DT comparison_NN between_IN the_DT experimental_JJ and_CC control_NN
        subjects_NNS revealed_VBD that_IN they_PRP were_VBD of_IN comparable_JJ age_NN and_CC sex_NN
        (_( Table_NNP I_PRP )_) ._. Operative_NNP indications_NNS ,_, procedures_NNS and_CC surgical_JJ
        variables_NNS were_VBD likewise_RB similar_JJ in_IN the_DT two_CD groups_NNS of_IN
        patients_NNS (_( Table_NNP I_PRP )_) ._. A_DT significant_JJ difference_NN was_VBD noted_VBN
        however_RB in_IN that_IN the_DT patients_NNS in_IN the_DT experimental_JJ group_NN had_VBD
        a_DT significantly_RB higher_JJR percentage_NN of_IN patients_NNS with_IN a_DT
        personal_NN or_CC family_NN history_NN of_IN thromboembolism_NN (_( p_NN <_NN 0_CD ._. 001_CD
        for_IN both_DT )_) ._.
        The_DT Factor_NN V_NNP Leiden_NNP mutation_NN was_VBD present_JJ in_IN none_NN of_IN the_DT
        38_CD experimental_JJ patients_NNS and_CC in_IN 3_CD %_NN or_CC 8_CD of_IN the_DT 241_CD controls_NNS
        (_( p_NN =_SYM 0_CD ._. 26_CD ._. Odds_NNS ratio_NN =_SYM 1_CD with_IN 95_CD %_NN confidence_NN interval_NN
        0_CD -_: 3_CD ._. 8_CD )_) ._. Post-hoc_NNP power_NN analysis_NN revealed_VBD that_IN with_IN the_DT
        number_NN of_IN subjects_NNS available_JJ ,_, the_DT minimum_JJ detectable_JJ risk_NN
        for_IN the_DT Factor_NN V_NNP Leiden_NNP mutation_NN being_VBG associated_VBN with_IN a_DT
        higher_JJR risk_NN of_IN thromboembolic_JJ complications_NNS was_VBD 5_CD ._. 9_CD ._.
        Similarly_RB there_EX was_VBD no_DT difference_NN detected_VBD in_IN the_DT
        distribution_NN of_IN polymorphisms_NNS for_IN the_DT Angiotensin_NNP
        Converting_NNP Enzyme_NNP gene_NN with_IN the_DT deletion-deletion_JJ genotype_NN
        present_JJ in_IN 36_CD %_NN or_CC 13_CD of_IN the_DT 38_CD experimental_JJ patients_NNS and_CC in_IN
        31_CD %_NN or_CC 74_CD of_IN the_DT 241_CD controls_NNS (_( p_NN =_SYM 0_CD ._. 32_CD ._. Odds_NNS ratio_NN =_SYM 1_CD ._. 2_CD
        with_IN 95_CD %_NN confidence_NN interval_NN 0_CD ._. 5_CD -_: 2_CD ._. 5_LS )_) ._. Post-hoc_NNP power_NN
        analysis_NN revealed_VBD that_IN with_IN the_DT number_NN of_IN subjects_NNS
        available_JJ ,_, the_DT minimum_JJ detectable_JJ risk_NN for_IN the_DT
        deletion-deletion_JJ polymorphism_NN of_IN the_DT ACE_NNP gene_NN being_VBG
        associated_VBN with_IN a_DT higher_JJR risk_NN of_IN thromboembolic_JJ
        complications_NNS was_VBD 2_CD ._. 7_CD ._.
      
      
        Discussion_NNP
        Previous_JJ authors_NNS have_VBP examined_VBN the_DT relationship_NN between_IN
        inherited_VBN hypercoagulable_JJ states_NNS and_CC thromboembolism_NN
        following_VBG total_JJ hip_NN and_CC knee_NN arthroplasty_NN with_IN mixed_JJ
        results_NNS ._. Lowe_NNP et_CC al_NN ._. [_NN 19_CD ]_NN found_VBD that_IN the_DT Factor_NN V_NNP Leiden_NNP
        mutation_NN was_VBD associated_VBN with_IN an_DT increased_VBN risk_NN of_IN deep_JJ
        venous_JJ thrombosis_NNS (_( as_IN determined_VBN by_IN routine_JJ bilateral_JJ
        ascending_VBG venography_NN )_) in_IN 480_CD European_JJ patients_NNS who_WP had_VBD
        undergone_VBN total_JJ hip_NN arthroplasty_NN ,_, however_RB only_RB 41_CD of_IN the_DT
        120_CD patients_NNS with_IN deep_JJ venous_JJ thrombosis_NNS had_VBD proximal_NN
        thrombi_NN ._. Svensson_NNP et_CC al_NN ._. [_NN 20_CD ]_NN found_VBD that_IN among_IN a_DT cohort_NN of_IN
        100_CD Swedish_JJ patients_NNS who_WP had_VBD undergone_VBN hip_NN arthroplasty_NN ,_,
        female_JJ patients_NNS who_WP were_VBD heterozygous_JJ for_IN the_DT factor_NN V_NNP
        Leiden_NNP mutation_NN had_VBD a_DT four-fold_RB increased_VBN risk_NN of_IN
        thrombosis_NNS ._. The_DT authors_NNS felt_VBD ,_, however_RB ,_, that_WDT based_VBN on_IN their_PRP$
        data_NNS ,_, no_DT definite_JJ association_NN between_IN the_DT Factor_NN V_NNP Leiden_NNP
        mutation_NN and_CC postoperative_JJ thrombosis_NNS could_MD be_VB made_VBN ._. In_IN
        contrast_NN ,_, Ryan_NNP et_CC al_NN ._. [_NN 21_CD ]_NN studied_VBD 825_CD patients_NNS who_WP had_VBD
        routine_JJ bilateral_JJ ascending_VBG venography_NN following_VBG total_JJ hip_NN
        and_CC knee_NN arthroplasty_NN and_CC found_VBD that_IN the_DT prevalence_NN of_IN the_DT
        Factor_NN V_NNP Leiden_NNP mutation_NN was_VBD no_DT different_JJ between_IN patients_NNS
        who_WP did_VBD and_CC did_VBD not_RB have_VB venographic_JJ evidence_NN of_IN deep_JJ
        venous_JJ thrombosis_NNS ._. Similarly_RB ,_, Woolson_NNP et_CC al_NN ._. [_NN 22_CD ]_NN studied_VBD
        36_CD patients_NNS who_WP had_VBD a_DT proximal_NN deep_JJ venous_JJ thrombosis_NNS after_IN
        total_JJ hip_NN arthroplasty_NN (_( detected_VBN by_IN routine_JJ predischarge_NN
        compression_NN duplex_NN ultrasound_NN )_) and_CC found_VBD that_IN the_DT
        prevalence_NN of_IN the_DT Factor_NN V_NNP Leiden_NNP was_VBD no_DT different_JJ in_IN that_DT
        population_NN compared_VBN to_TO 45_CD controls_NNS ._. In_IN contrast_NN to_TO the_DT
        aforementioned_JJ studies_NNS ,_, the_DT present_JJ report_NN studied_VBD patients_NNS
        who_WP had_VBD developed_VBN symptomatic_JJ thromboembolic_JJ events_NNS (_( the_DT
        majority_NN of_IN which_WDT were_VBD pulmonary_JJ embolism_NN )_) and_CC were_VBD all_DT
        treated_VBN with_IN a_DT uniform_NN thromboembolic_JJ prophylaxis_NNS regime_NN ._.
        Our_PRP$ results_NNS support_VBP the_DT findings_NNS of_IN others_NNS ,_, that_IN in_IN
        patients_NNS receiving_VBG pharmacological_JJ prophylaxis_NNS against_IN
        postoperative_JJ thrombosis_NNS ,_, the_DT Factor_NN V_NNP Leiden_NNP mutation_NN is_VBZ
        not_RB associated_VBN with_IN an_DT increased_VBN risk_NN of_IN symptomatic_JJ
        thromboembolism_NN following_VBG total_JJ hip_NN or_CC knee_NN
        arthroplasty_NN ._.
        While_IN Phillip_NNP et_CC al_NN ._. [_NN 23_CD ]_NN found_VBD no_DT association_NN between_IN
        the_DT Factor_NN V_NNP Leiden_NNP mutation_NN and_CC deep_JJ venous_JJ thrombosis_NNS ,_,
        they_PRP did_VBD find_VB that_IN the_DT deletion-deletion_JJ genotype_NN of_IN the_DT
        angiotensin_NN converting_VBG enzyme_NN was_VBD strongly_RB associated_VBN with_IN
        postoperative_JJ venous_JJ thrombosis_NNS in_IN 85_CD patients_NNS who_WP had_VBD
        undergone_VBN total_JJ hip_NN arthroplasty_NN (_( 30_CD of_IN whom_WP had_VBD a_DT
        thromboembolic_JJ event_NN as_IN detected_VBN by_IN routine_JJ compression_NN
        duplex_NN ultrasound_NN )_) ._. They_PRP concluded_VBD that_IN patients_NNS with_IN the_DT
        deletion_NN /_NN deletion_NN genotype_NN were_VBD at_IN a_DT 10_CD -_: fold_VB increased_VBN risk_NN
        for_IN a_DT thromboembolic_JJ event_NN following_VBG total_JJ hip_NN arthroplasty_NN
        as_IN compared_VBN to_TO patients_NNS with_IN the_DT insertion-insertion_JJ
        genotype_NN ._. However_RB ,_, 12_CD of_IN the_DT 30_CD experimental_JJ subjects_NNS had_VBD
        isolated_VBN distal_NN deep_JJ venous_JJ thrombosis_NNS (_( which_WDT is_VBZ of_IN
        questionable_JJ clinical_JJ significance_NN )_) and_CC only_RB 10_CD %_NN had_VBD a_DT
        pulmonary_JJ embolism_NN ._. While_IN the_DT results_NNS of_IN this_DT study_NN had_VBD
        encouraged_VBN us_PRP to_TO screen_VB our_PRP$ patient_NN population_NN for_IN these_DT
        polymorphisms_NNS ,_, when_WRB utilizing_VBG a_DT more_RBR relevant_JJ clinical_JJ
        endpoint_NN (_( symptomatic_JJ pulmonary_JJ embolism_NN or_CC deep_JJ venous_JJ
        thrombosis_NNS )_) we_PRP were_VBD unable_JJ to_TO confirm_VB this_DT association_NN ._.
        Due_JJ to_TO the_DT relative_JJ infrequence_NN of_IN symptomatic_JJ
        thromboembolic_JJ events_NNS while_IN using_VBG pharmacological_JJ agents_NNS as_IN
        prophylaxis_NNS ,_, an_DT unmatched_JJ case-control_JJ study_NN design_NN was_VBD
        employed_VBN ._. This_DT type_NN of_IN study_NN design_NN has_VBZ the_DT advantage_NN of_IN
        increased_VBN statistical_JJ power_NN for_IN studying_VBG relatively_RB rare_JJ
        events_NNS [_NN 24_CD ]_NN ._. However_RB ,_, its_PRP$ disadvantages_NNS include_VBP the_DT
        possibility_NN that_IN other_JJ variables_NNS that_WDT were_VBD not_RB controlled_VBN
        for_IN could_MD have_VB affected_VBN our_PRP$ results_NNS ._. The_DT patients_NNS in_IN both_DT
        the_DT case_NN and_CC control_NN groups_NNS were_VBD operated_VBN on_IN during_IN
        overlapping_VBG time_NN periods_NNS and_CC were_VBD found_VBN to_TO be_VB
        demographically_RB similar_JJ ,_, and_CC thus_RB we_PRP do_VBP not_RB believe_VB that_IN
        such_JJ confounding_VBG variables_NNS affected_VBD our_PRP$ results_NNS ._. Our_PRP$ power_NN
        analysis_NN reveals_VBZ that_IN a_DT relatively_RB strong_JJ association_NN
        between_IN these_DT genetic_JJ profiles_NNS and_CC postoperative_JJ
        thromboembolism_NN (_( 5_CD ._. 9_CD fold_VB increased_VBN risk_NN for_IN the_DT factor_NN V_NNP
        Leiden_NNP mutation_NN and_CC a_DT 2_CD ._. 7_CD fold_VB increased_VBN risk_NN for_IN the_DT
        deletion_NN /_NN deletion_NN polymorphism_NN of_IN the_DT angiotensin_NN
        converting_VBG enzyme_NN gene_NN )_) would_MD have_VB been_VBN required_VBN to_TO detect_VB
        a_DT significant_JJ difference_NN between_IN the_DT prevalence_NN of_IN these_DT
        mutations_NNS in_IN our_PRP$ case_NN and_CC control_NN groups_NNS ._. Likewise_RB ,_, a_DT
        larger_JJR number_NN of_IN patients_NNS would_MD have_VB been_VBN required_VBN to_TO find_VB
        a_DT significant_JJ difference_NN if_IN a_DT weaker_JJR association_NN was_VBD
        assumed_VBN ._. However_RB ,_, no_DT trend_NN was_VBD detected_VBN in_IN our_PRP$ data_NNS to_TO
        suggest_VB that_IN such_JJ an_DT association_NN was_VBD present_JJ ._. Furthermore_RB ,_,
        such_JJ a_DT weak_JJ association_NN would_MD make_VB preoperative_JJ screening_NN
        and_CC identification_NN of_IN such_JJ patients_NNS not_RB cost_VB effective_JJ ._.
        It_PRP was_VBD noted_VBN however_RB ,_, that_IN a_DT significantly_RB greater_JJR
        percentage_NN of_IN patients_NNS who_WP suffered_VBD a_DT thromboembolic_JJ event_NN
        had_VBD a_DT personal_NN or_CC family_NN history_NN of_IN thromboembolism_NN (_( p_NN =_SYM
        0_CD ._. 001_CD for_IN both_DT )_) ._. The_DT report_NN by_IN Woolson_NNP et_CC al_NN ._. [_NN 22_CD ]_NN
        included_VBD similar_JJ findings_NNS ._. Although_IN residual_JJ abnormalities_NNS
        of_IN the_DT deep_JJ venous_JJ system_NN could_MD account_VB for_IN the_DT higher_JJR
        prevalence_NN of_IN a_DT personal_JJ history_NN of_IN prior_JJ deep_JJ venous_JJ
        thrombosis_NNS or_CC pulmonary_JJ embolism_NN ,_, the_DT higher_JJR prevalence_NN of_IN
        a_DT family_NN history_NN of_IN thromboembolic_JJ events_NNS suggests_VBZ that_IN an_DT
        as_RB yet_RB undescribed_JJ genetically_RB determined_VBN hypercoagulable_JJ
        state_NN or_CC predisposition_NN may_MD be_VB present_JJ in_IN these_DT
        patients_NNS ._.
      
      
        Conclusions_NNP
        The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO determine_VB whether_IN a_DT
        specific_JJ genetic_JJ profile_NN is_VBZ associated_VBN with_IN a_DT higher_JJR risk_NN
        of_IN developing_VBG a_DT postoperative_JJ thromboembolic_JJ complication_NN ._.
        Although_IN our_PRP$ results_NNS suggest_VBP that_IN neither_DT of_IN these_DT
        potentially_RB hypercoaguable_JJ states_NNS are_VBP associated_VBN with_IN an_DT
        increased_VBN risk_NN of_IN symptomatic_JJ thromboembolic_JJ events_NNS
        following_VBG total_JJ hip_NN or_CC knee_NN arthroplasty_NN in_IN patients_NNS
        receiving_VBG pharmacological_JJ thromboprophylaxis_NNS ,_, an_DT as_RB yet_RB
        undescribed_JJ genetically_RB determined_VBN hypercoagulable_JJ state_NN or_CC
        predisposition_NN may_MD be_VB present_JJ in_IN these_DT patients_NNS ._.
      
    
  
